Search | Clinical Trials Finder

Conditions: Prostate Adenocarcinoma
Interventions: Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix; Drug · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 49
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Daly City, California + 46 more

Conditions: Prostate Cancer
Interventions: Radium Ra 223 Dichloride, Enzalutamide; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions: Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Duarte, California • Los Angeles, California • Orange, California + 24 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more

Conditions: Multiple Myeloma
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more

Conditions: Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer
Interventions: Niraparib, Radium Ra 223 Dichloride; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • New Orleans, Louisiana + 2 more

Conditions: Prostate Cancer Metastatic to Bone
Interventions: Radium Ra 223 Dichloride, Radiation; Drug · Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more

Conditions: Breast Cancer
Interventions: Ra-223 dichloride, Denosumab, Hormone Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castrate Resistant Prostate Cancer
Interventions: Docetaxel, Radium 223; Drug · Radiation
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio

Conditions: Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
Interventions: Tasquinimod, Radium 223; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non Small Cell Lung Cancer With Bone Metastatses
Interventions: Xofigo; Biological
Lead sponsor: Angela Taber MD; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Prostatic Neoplasm
Interventions: Xofigo (Radium 223 dichloride,BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more

Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 29
States / cities: Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 12
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Fort Myers, Florida + 9 more

Conditions: Sarcoma
Interventions: Ra-223 Dichloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer Metastatic
Interventions: Not listed
Lead sponsor: Carolina Research Professionals, LLC; Other
Eligibility: Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Prednisone, Radium-223 dichloride, cabazitaxel, Carboplatin, Enzalutamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Radium dichloride, PET Scan; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Aurora, Colorado • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more

Conditions: Prostate Carcinoma Metastatic to the Bone
Interventions: Enzalutamide, Radium ra 223 dichloride; Drug · Radiation
Lead sponsor: Carolina Research Professionals, LLC; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Towson, Maryland • Syracuse, New York • Myrtle Beach, South Carolina + 1 more

Search by objective public record fields.

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

Treatment Patterns in Metastatic Prostate Cancer

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis